$CYDY
CytoDyn Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024013320 Filed on October 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $1.604M $2.688M
YoY Change -40.33% -57.56%
% of Gross Profit
Research & Development $1.914M
YoY Change 232.29%
% of Gross Profit
Depreciation & Amortization $5.000K $10.00K
YoY Change -50.0% -89.9%
% of Gross Profit
Operating Expenses -$22.44M $1.914M
YoY Change -1272.26% 232.29%
Operating Profit $22.44M -$4.612M
YoY Change -586.49% -52.51%
Interest Expense -$2.016M -$1.959M
YoY Change 2.91% -81.05%
% of Operating Profit -8.99%
Other Income/Expense, Net -$14.00K -$912.0K
YoY Change -98.46% -2.98%
Pretax Income $19.23M -$11.57M
YoY Change -266.17% -44.88%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $19.23M -$11.57M
YoY Change -266.17% -44.88%
Net Earnings / Revenue
Basic Earnings Per Share $0.02 -$0.01
Diluted Earnings Per Share $0.02 -$0.01
COMMON SHARES
Basic Shares Outstanding 1.215B 931.0M
Diluted Shares Outstanding 1.198B 923.6M

Balance Sheet

Concept 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.92M $2.034M
YoY Change 1125.22% -56.5%
Cash & Equivalents $24.92M $2.034M
Short-Term Investments
Other Short-Term Assets $817.0K $9.934M
YoY Change -91.78% 91.74%
Inventory
Prepaid Expenses $570.0K $2.858M
Receivables
Other Receivables
Total Short-Term Assets $27.74M $11.97M
YoY Change 131.77% 21.42%
LONG-TERM ASSETS
Property, Plant & Equipment $230.0K $366.0K
YoY Change -37.16% -27.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $283.0K $443.0K
YoY Change -36.12% -27.14%
Total Long-Term Assets $283.0K $443.0K
YoY Change -36.12% -97.61%
TOTAL ASSETS
Total Short-Term Assets $27.74M $11.97M
Total Long-Term Assets $283.0K $443.0K
Total Assets $28.02M $12.41M
YoY Change 125.78% -56.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.16M $62.80M
YoY Change -77.45% -8.99%
Accrued Expenses $26.48M $26.23M
YoY Change 0.95% 59.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $28.92M $33.10M
YoY Change -12.63% -10.13%
Total Short-Term Liabilities $69.56M $129.1M
YoY Change -46.1% 5.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $43.57M $247.0K
YoY Change 17540.08% -36.18%
Total Long-Term Liabilities $43.57M $247.0K
YoY Change 17540.08% -36.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $69.56M $129.1M
Total Long-Term Liabilities $43.57M $247.0K
Total Liabilities $113.2M $129.3M
YoY Change -12.43% 5.37%
SHAREHOLDERS EQUITY
Retained Earnings -$872.3M -$853.3M
YoY Change 2.23% 9.0%
Common Stock $1.220M $931.0K
YoY Change 31.04% 14.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$85.21M -$116.9M
YoY Change
Total Liabilities & Shareholders Equity $28.02M $12.41M
YoY Change 125.78% -56.29%

Cashflow Statement

Concept 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income $19.23M -$11.57M
YoY Change -266.17% -44.88%
Depreciation, Depletion And Amortization $5.000K $10.00K
YoY Change -50.0% -89.9%
Cash From Operating Activities $5.440M -$4.495M
YoY Change -221.02% -59.41%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.667M 4.019M
YoY Change 140.53% -65.11%
NET CHANGE
Cash From Operating Activities 5.440M -4.495M
Cash From Investing Activities 0.000
Cash From Financing Activities 9.667M 4.019M
Net Change In Cash 15.11M -476.0K
YoY Change -3273.74% -206.97%
FREE CASH FLOW
Cash From Operating Activities $5.440M -$4.495M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001175680
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.cytodyn.com/20240831#AccruedCompensationAndNonFinancingLiabilities
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2024Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.cytodyn.com/20240831#AccruedCompensationAndNonFinancingLiabilities
CY2024Q3 dei Amendment Flag
AmendmentFlag
false
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-08-31
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity File Number
EntityFileNumber
000-49908
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
CYTODYN INC.
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1887078
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Main Street
CY2024Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 660
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
CY2024Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98660
CY2024Q3 dei City Area Code
CityAreaCode
360
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
980-8524
CY2024Q3 dei Security12b Title
Security12bTitle
None
CY2024Q3 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1219842000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24921000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3110000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6704000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
570000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
463000
CY2024Q3 cydy Prepaid Service Fees Current
PrepaidServiceFeesCurrent
247000
CY2024Q2 cydy Prepaid Service Fees Current
PrepaidServiceFeesCurrent
538000
CY2024Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
2000000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
27738000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
10815000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
283000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
321000
CY2024Q3 us-gaap Assets
Assets
28021000
CY2024Q2 us-gaap Assets
Assets
11136000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
14159000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
29561000
CY2024Q3 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
2923000
CY2024Q2 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
2810000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
16392000
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
15227000
CY2024Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
7163000
CY2024Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
6791000
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
28918000
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
29793000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
69555000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
84182000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
141000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43571000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43571000
CY2024Q3 us-gaap Liabilities
Liabilities
113231000
CY2024Q2 us-gaap Liabilities
Liabilities
127894000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1750000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1750000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1220284000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1059002000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1219841000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1058559000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1220000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1059000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
443000
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
443000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
785874000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
773714000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-872304000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-891531000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-85210000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-116758000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28021000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11136000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1604000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2688000
CY2024Q3 cydy Research And Development Income Expense
ResearchAndDevelopmentIncomeExpense
-24046000
CY2023Q3 cydy Research And Development Income Expense
ResearchAndDevelopmentIncomeExpense
1914000
CY2024Q3 us-gaap Depreciation
Depreciation
5000
CY2023Q3 us-gaap Depreciation
Depreciation
10000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
-22437000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
4612000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
22437000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4612000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
126000
CY2024Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1165000
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1197000
CY2024Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
125000
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
366000
CY2024Q3 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
1180000
CY2023Q3 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
2004000
CY2024Q3 cydy Finance Charge Adjustments
FinanceChargeAdjustments
14000
CY2023Q3 cydy Finance Charge Adjustments
FinanceChargeAdjustments
912000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2084000
CY2024Q3 cydy Gain Loss On Derivatives
GainLossOnDerivatives
-852000
CY2023Q3 cydy Gain Loss On Derivatives
GainLossOnDerivatives
4000
CY2024Q3 cydy Interest And Nonoperating Income Expense
InterestAndNonoperatingIncomeExpense
-3210000
CY2023Q3 cydy Interest And Nonoperating Income Expense
InterestAndNonoperatingIncomeExpense
-6959000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19227000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11571000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
19227000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11571000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135043000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
923587000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1198287000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
923587000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-116758000
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000000
CY2024Q3 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
1180000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14026000
CY2024Q3 cydy Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Excluding Legal Fees
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsExcludingLegalFees
3649000
CY2024Q3 cydy Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends
AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends
-372000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
136000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
19227000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-85210000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-109501000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1500000
CY2023Q3 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
2004000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
170000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
155000
CY2023Q3 cydy Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
300000
CY2023Q3 cydy Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends
AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends
373000
CY2023Q3 cydy Reclassification Of Warrants From Liability To Equity Classified
ReclassificationOfWarrantsFromLiabilityToEquityClassified
79000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
348000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11571000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-116889000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
19227000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11571000
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
10000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
366000
CY2024Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
125000
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400000
CY2024Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-852000
CY2023Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
4000
CY2024Q3 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
1180000
CY2023Q3 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
2004000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2084000
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
136000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
503000
CY2024Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1783000
CY2023Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1605000
CY2024Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-14302000
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3318000
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5440000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4495000
CY2024Q3 cydy Proceeds From Warrant Transactions Net
ProceedsFromWarrantTransactionsNet
10377000
CY2023Q3 cydy Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
2575000
CY2023Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
300000
CY2024Q3 cydy Proceeds From Convertible Note And Warrant Issuances
ProceedsFromConvertibleNoteAndWarrantIssuances
-710000
CY2023Q3 cydy Proceeds From Convertible Note And Warrant Issuances
ProceedsFromConvertibleNoteAndWarrantIssuances
1144000
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9667000
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4019000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15107000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-476000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9814000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9048000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24921000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8572000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24921000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2034000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6538000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24921000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8572000
CY2024Q3 us-gaap Interest Paid Net
InterestPaidNet
45000
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
24000
CY2023Q3 cydy Noncash Derivative Liability Associated With Warrants
NoncashDerivativeLiabilityAssociatedWithWarrants
83000
CY2024Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1000000
CY2023Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1500000
CY2024Q3 cydy Dividends On Convertible Preferred Stock Incurred But Not Yet Paid.
DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.
372000
CY2023Q3 cydy Dividends On Convertible Preferred Stock Incurred But Not Yet Paid.
DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.
373000
CY2023Q3 cydy Warrants Issued To Placement Agent
WarrantsIssuedToPlacementAgent
413000
CY2023Q3 cydy Note Conversion To Common Stock And Warrants
NoteConversionToCommonStockAndWarrants
2295000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-872300000
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Use of estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited consolidated financial statements have been prepared in accordance with GAAP, which requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates are assessed each period and updated to reflect current information, such as the status of our analysis of the results of our clinical trials and/or discussions with the U.S. Food and Drug Administration (“FDA”), which could have an impact on the Company’s significant accounting estimates and assumptions. The Company’s estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include, but are not limited to, those relating to stock-based compensation, the assumptions used to value warrants and warrant modifications. Actual results could differ from these estimates.<span style="white-space:pre-wrap;"> </span></p>
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
362000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
208000
CY2024Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
101000
CY2024Q2 us-gaap Litigation Reserve Current
LitigationReserveCurrent
7000
CY2024Q3 cydy Accrued Clinical Expenses
AccruedClinicalExpenses
143000
CY2024Q2 cydy Accrued Clinical Expenses
AccruedClinicalExpenses
329000
CY2024Q3 cydy Accrued License Fees Current
AccruedLicenseFeesCurrent
2033000
CY2024Q2 cydy Accrued License Fees Current
AccruedLicenseFeesCurrent
1799000
CY2024Q3 cydy Accrued Lease Payable
AccruedLeasePayable
142000
CY2024Q2 cydy Accrued Lease Payable
AccruedLeasePayable
142000
CY2024Q2 cydy Investor Proceeds Held In Escrow
InvestorProceedsHeldInEscrow
300000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
142000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25000
CY2024Q3 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
2923000
CY2024Q2 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
2810000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
29200000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30200000
CY2024Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
282000
CY2024Q2 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
407000
CY2024Q3 cydy Long Term Debt Including Accrued Interest
LongTermDebtIncludingAccruedInterest
28918000
CY2024Q2 cydy Long Term Debt Including Accrued Interest
LongTermDebtIncludingAccruedInterest
29793000
CY2024Q3 cydy Accrued Interest Noncurrent
AccruedInterestNoncurrent
16392000
CY2024Q2 cydy Accrued Interest Noncurrent
AccruedInterestNoncurrent
15227000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
45310000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
45020000
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
45020000
CY2024Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
125000
CY2024Q3 cydy Interest Expense Accrued
InterestExpenseAccrued
1165000
CY2024Q3 cydy Debt Conversion Fair Market Value Of Shares Exchanged For Repayment
DebtConversionFairMarketValueOfSharesExchangedForRepayment
1180000
CY2024Q3 cydy Changes In Fair Value Of Common Stocks Of Convertible Debt
ChangesInFairValueOfCommonStocksOfConvertibleDebt
180000
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
45310000
CY2023Q2 cydy Number Of Share In Unit
NumberOfShareInUnit
1
CY2023Q2 cydy Number Of Warrant In Unit
NumberOfWarrantInUnit
1
CY2023Q2 cydy Deemed Purchase Price As Percentage Of Lower Intraday Volume Weighted Average Price
DeemedPurchasePriceAsPercentageOfLowerIntradayVolumeWeightedAveragePrice
0.90
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.306
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
127100000
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.09387
CY2024Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11900000
CY2024Q3 cydy Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
10400000
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
25400000
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1400000
CY2024Q3 cydy Percentage Of Gross Proceeds
PercentageOfGrossProceeds
0.13
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.09387
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1400000
CY2024Q3 us-gaap Legal Fees
LegalFees
100000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1700000
CY2024Q3 cydy Fair Value Adjustment Of Warrants Repricing
FairValueAdjustmentOfWarrantsRepricing
400000
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
361445
CY2024Q2 cydy Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice
0.34
CY2024 cydy Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm
P4Y2M15D
CY2024Q2 cydy Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue
2697000
CY2024Q3 cydy Class Of Warrants Or Rights Exercised
ClassOfWarrantsOrRightsExercised
127087
CY2024Q3 cydy Class Of Warrants Or Rights Exercised Weighted Average Exercise Price
ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice
0.09
CY2024Q3 cydy Class Of Warrants Or Rights Forfeited Expired And Cancelled
ClassOfWarrantsOrRightsForfeitedExpiredAndCancelled
2110
CY2024Q3 cydy Class Of Warrants Or Rights Forfeited Expired And Cancelled Weighted Average Exercise Price
ClassOfWarrantsOrRightsForfeitedExpiredAndCancelledWeightedAverageExercisePrice
0.43
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
232248
CY2024Q3 cydy Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice
0.26
CY2024Q3 cydy Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm
P4Y3M10D
CY2024Q3 cydy Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue
5045000
CY2024Q3 cydy Class Of Warrant Or Right Outstanding And Exercisable
ClassOfWarrantOrRightOutstandingAndExercisable
232248
CY2024Q3 cydy Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Exercise Price
ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageExercisePrice
0.26
CY2024Q3 cydy Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageRemainingContractualTerm
P4Y3M10D
CY2024Q3 cydy Class Of Warrants Or Rights Outstanding And Exercisable Aggregate Intrinsic Value
ClassOfWarrantsOrRightsOutstandingAndExercisableAggregateIntrinsicValue
5045000
CY2024Q3 cydy Share Based Compensation Number Of Active Plans
ShareBasedCompensationNumberOfActivePlans
1
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
19227000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11571000
CY2024Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
372000
CY2023Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
373000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
18855000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11944000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135043000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
923587000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
18855000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11944000
CY2024Q3 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
372000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
19227000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11944000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135043000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
923587000
CY2024Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
25450000
CY2024Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
37794000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1198287000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
923587000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
32000.0
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
42600
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
230000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
264000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
142000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
142000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
141000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
247000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
283000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
139000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
169000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
308000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
61000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
247000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100

Files In Submission

Name View Source Status
0001558370-24-013320-index-headers.html Edgar Link pending
0001558370-24-013320-index.html Edgar Link pending
0001558370-24-013320.txt Edgar Link pending
0001558370-24-013320-xbrl.zip Edgar Link pending
cydy-20240831.xsd Edgar Link pending
cydy-20240831x10q.htm Edgar Link pending
cydy-20240831xex31d1.htm Edgar Link pending
cydy-20240831xex31d2.htm Edgar Link pending
cydy-20240831xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
cydy-20240831_cal.xml Edgar Link unprocessable
cydy-20240831_def.xml Edgar Link unprocessable
cydy-20240831_lab.xml Edgar Link unprocessable
cydy-20240831_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cydy-20240831x10q_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending